Should This Prostate Drug Be Used For Cancer Prevention?
Should the Proscar pill and various generic versions be used to prevent prostate cancer? This question will likely be debated extensively thanks to a new study clarifying decade-old concerns that the drug, known as finasteride, may boost the risk of developing aggressive, high-grade tumors. The issue was first raised in a 2003 study that found the drug lowered the risk of developing prostate cancer by 30 percent.
As a result of that earlier study, the FDA never approved finasteride for preventing prostate cancer and, instead, required warnings on the product labeling to thwart an unapproved use. (The drug is approved to sh...
Source: Pharmalot - August 15, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
New Update On Prostate Cancer Prevention With Finasteride Creates A Dilemma For Patients
We've all heard the phrase, "When you come to a fork in the road, take it." Well, that saying may hold particular relevance while reviewing a new research report published today in the New England Journal of Medicine.
The report is an important one. It is an 18 year follow-up of a study designed to show whether the use of the drug finasteride could reduce the incidence and deaths from prostate cancer. The study was called the Prostate Cancer Prevention Trial and when it was initially reported in 2003 it showed that the drug could reduce the incidence of prostate cancer by almost 25%. However, there was a...
Source: Dr. Len's Cancer Blog - August 14, 2013 Category: Cancer Authors: Dr. Len Tags: Cancer Care Early detection Medications Prevention Prostate Cancer Radiation Therapy Research Screening Treatment Source Type: blogs
Six ways Big Pharma manipulates consumers - Salon
This article originally appeared on AlterNet.
The blockbuster pill profit party is over for Big Pharma. Bestselling pills like Lipitor, Seroquel, Zyprexa, Singular and Concerta have gone off patent and sites which their ads sustained are withering on the vine. WebMD, for example, the voice of Pharma on the Web, with a former Pfizer exec serving as CEO, announced it would cut 250 positions in December.
But don’t worry, Wall Street. Pharma isn’t going to deliver disappointing earnings just because it has little or no new drugs coming online and has failed at the very reason for its existence. Here are six new Pharma ma...
Source: PharmaGossip - April 28, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
